메뉴 건너뛰기




Volumn 11, Issue SUPPL. 10, 2006, Pages 1-11

Are we treating schizophrenia effectively? Understanding the primary outcomes of the catie study

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

EID: 33748929105     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025748     Document Type: Review
Times cited : (8)

References (13)
  • 2
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • Epub 2005 Sep 19
    • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. Epub 2005 Sep 19.
    • (2005) N Engl J Med , vol.353 , Issue.12 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 3
    • 85047698267 scopus 로고    scopus 로고
    • Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    • McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;16(4):600-610.
    • (2006) Am J Psychiatry , vol.16 , Issue.4 , pp. 600-610
    • McEvoy, J.P.1    Lieberman, J.A.2    Stroup, T.S.3
  • 4
    • 85047695988 scopus 로고    scopus 로고
    • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    • Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622.
    • (2006) Am J Psychiatry , vol.163 , Issue.4 , pp. 611-622
    • Stroup, T.S.1    Lieberman, J.A.2    McEvoy, J.P.3
  • 5
    • 0038448311 scopus 로고    scopus 로고
    • The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
    • Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31.
    • (2003) Schizophr Bull , vol.29 , Issue.1 , pp. 15-31
    • Stroup, T.S.1    McEvoy, J.P.2    Swartz, M.S.3
  • 6
    • 23044516620 scopus 로고    scopus 로고
    • Metabolic issues in patients with severe mental illness
    • Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with severe mental illness. South Med J. 2005;98(7):714-720.
    • (2005) South Med J , vol.98 , Issue.7 , pp. 714-720
    • Citrome, L.1    Blonde, L.2    Damatarca, C.3
  • 7
    • 33748924643 scopus 로고    scopus 로고
    • Antipsychotic drug treatment of schizophrenia: Update on the CATIE trial
    • June 1-4, 2004, Phoenix, Arizona. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Bethesda, MD
    • Stroup TS (2004) Antipsychotic drug treatment of schizophrenia: update on the CATIE trial. In: NCDEU Abstracts from the 44th Annual Meeting, June 1-4, 2004, Phoenix, Arizona. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Bethesda, MD.
    • (2004) NCDEU Abstracts from the 44th Annual Meeting
    • Stroup, T.S.1
  • 8
    • 27744502054 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    • Epub 2005 Aug 30
    • McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. Epub 2005 Aug 30.
    • (2005) Schizophr Res , vol.80 , Issue.1 , pp. 19-32
    • McEvoy, J.P.1    Meyer, J.M.2    Goff, D.C.3
  • 9
    • 33747180826 scopus 로고    scopus 로고
    • Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
    • Jul [Epub ahead of print]
    • Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Jul 31; [Epub ahead of print].
    • (2006) Schizophr Res , vol.31
    • Nasrallah, H.A.1    Meyer, J.M.2    Goff, D.C.3
  • 10
    • 1642283731 scopus 로고    scopus 로고
    • Practice guideline for the treatment of patients with schizophrenia, second edition
    • Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
    • (2004) Am J Psychiatry , vol.161 , Issue.2 SUPPL. , pp. 1-56
    • Lehman, A.F.1    Lieberman, J.A.2    Dixon, L.B.3
  • 11
    • 0037771503 scopus 로고    scopus 로고
    • Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    • Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 2003;29(1):33-43.
    • (2003) Schizophr Bull , vol.29 , Issue.1 , pp. 33-43
    • Swartz, M.S.1    Perkins, D.O.2    Stroup, T.S.3    McEvoy, J.P.4    Nieri, J.M.5    Haak, D.C.6
  • 12
    • 33746115248 scopus 로고    scopus 로고
    • Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?
    • Citrome L, Stroup TS: Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006;60(8):933-940.
    • (2006) Int J Clin Pract , vol.60 , Issue.8 , pp. 933-940
    • Citrome, L.1    Stroup, T.S.2
  • 13
    • 84859271832 scopus 로고    scopus 로고
    • www.jr2.ox.ac.uk/bandolier/painres/download/whatis/NNT.pdf.
    • Moore A, McQuay HJ. What is an NNT? www.evidence-based-medicine.co.uk. 2001;1(1):2. Available at: www.jr2.ox.ac.uk/bandolier/painres/download/whatis/ NNT.pdf. Accessed: June 8, 2006.
    • (2001) What Is An NNT? , vol.1 , Issue.1 , pp. 2
    • Moore, A.1    McQuay, H.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.